Back
Orgenesis 10K Form
Sell
18
ORGS
Orgenesis
Last Price:
4.13
Seasonality Move:
-8.05%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2020-08-06 | 10Q | ORGS/Orgenesis Quarterly |
| 2020-05-08 | 10Q | ORGS/Orgenesis Quarterly |
| 2020-03-09 | 10K | ORGS/Orgenesis Annual |
| 2019-11-07 | 10Q | ORGS/Orgenesis Quarterly |
| 2019-08-08 | 10Q | ORGS/Orgenesis Quarterly |
| 2019-05-08 | 10Q | ORGS/Orgenesis Quarterly |
Receive ORGS News And Ratings
See the #1 stock for the next 7 days that we like better than ORGS
ORGS Financial Statistics
Sales & Book Value
| Annual Sales: | $530K |
|---|---|
| Cash Flow: | $-5.91M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-3.30 |
| Price / Book: | 0 |
Profitability
| EPS (TTM): | -8.50000 |
|---|---|
| Net Income (TTM): | $-29.02M |
| Gross Margin: | $-5.73M |
| Return on Equity: | 0% |
| Return on Assets: | -82.38% |
Orgenesis Earnings Forecast
Key Orgenesis Financial Ratios
- The Gross Profit Margin over the past 16 years for ORGS is -1,080.19%.
- The Selling, General & Administrative Expenses for ORGS have been equal to 6,532.83% of Gross Profit Margin.
- The Research & Development expenses have been 2,091.89% of Revenue.
- The Interest Expense is -3.91% of Operating Income.
- The Net Earning history of ORGS is -10,445.47% of Total Revenues.
- Per Share Earnings over the last 16 years have been positive in 4 years.
Orgenesis Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | ORGS |
| CUSIP: | 68619K |
| Website: | orgenesis.com |
Debt
| Debt-to-Equity Ratio: | -0.72 |
|---|---|
| Current Ratio: | 0.07 |
| Quick Ratio: | 0.04 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |